Clinical impact of PTEN rs701848 as a predictive marker for breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Breast cancer risk increases with the PTEN rs701848T/C genetic variant. PTEN protein levels significantly decline with disease progression, indicating its potential as a predictive marker for breast cancer.
Area Of Science
- Oncology
- Genetics
- Molecular Biology
Background
- Breast cancer (BC) incidence is rising globally, making it the most prevalent female malignancy.
- PTEN (Phosphatase and tensin homolog) functions as a tumor suppressor by inhibiting the PI3K/AKT pathway.
- Understanding genetic variations in PTEN is crucial for BC research.
Purpose Of The Study
- To investigate the association between PTEN rs701848T/C genetic variants and breast cancer progression.
- To evaluate PTEN protein levels in breast cancer patients.
- To explore PTEN's utility as a predictive biomarker for breast cancer.
Main Methods
- Bioinformatic analysis was employed to study the PTEN rs701848T/C polymorphism.
- Genotyping was performed using qRT-PCR in 100 Egyptian BC patients and 50 healthy controls.
- PTEN protein levels were quantified via ELISA, correlating with clinical data.
Main Results
- The TC genotype of PTEN rs701848T/C was significantly more frequent in breast cancer patients (p=0.03).
- TC carriers exhibited increased risk of advanced tumor stage, larger tumor size, and metastasis.
- PTEN protein levels showed a significant decline correlating with disease progression and diagnostic accuracy.
Conclusions
- PTEN rs701848T/C polymorphism is linked to increased breast cancer risk and progression.
- Reduced PTEN protein levels are associated with advanced disease stages.
- PTEN holds promise as a predictive biomarker at both genomic and proteomic levels for breast cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...